The European Commission has approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents aged six and older. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in patients under 40 kg. The decision is based on positive results from Phase 3 OptIMMize trials showing safety and efficacy consistent with adult patients. This expands treatment options for pediatric psoriasis, a condition affecting nearly a third of patients before age 18, often impacting visible areas and quality of life.
AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilok...
AbbVie announced it will acquire Apogee Therapeutics, a clinical-stage biotech company, for approximately $10.9 billion. This acquisition gives AbbVie control over Apogee's diverse pipeline of clinical-stage candidates focused on inflammatory and imm...
The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disord...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, pote...
